Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.

Related collections

Most cited references 22

Record: found
Abstract: found
Article: not found

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

K. Ogurtsova, J.D. da Rocha Fernandes, Y. Huang … (2017)

To produce current estimates of the national, regional and global impact of diabetes for 2015 and 2040.

0 comments Cited 1334 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Terrance Barrett, Michele Weidner-Wells, Vlado Perkovic … (2018)

0 comments Cited 262 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

9. Cardiovascular Disease and Risk Management:Standards of Medical Care in Diabetes—2018

(2018)

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

0 comments Cited 170 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: New England Journal of Medicine (NEJM/MMS)

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: November 10 2018

Publication date (Electronic): November 10 2018

Affiliations

[1 ]From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.) — both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge...